Muscle-building peptides: evidence vs hype

The promise and the problem

Peptides marketed for muscle growth are heavily promoted online, but no peptide covered in this guide is FDA-approved for muscle building or athletic performance. Evidence quality varies enormously: some compounds have legitimate clinical data for related outcomes like fat reduction, while others rest entirely on rodent studies. This guide grades each one by evidence tier.

Peptides for muscle growth are among the most searched and most misunderstood topics in the biohacking space. Forums overflow with transformation photos and stacking claims, yet when those claims are traced back to their source, the evidence picture looks very different from the marketing.

The truth is that no peptide is FDA-approved specifically for muscle building or athletic performance. Some have legitimate clinical data for related outcomes (body composition, visceral fat reduction, tissue repair), while others rest entirely on rodent studies or anecdotal reports. Knowing which tier each peptide falls into is critical before evaluating any claim made about it.

This guide covers every major class of muscle-relevant peptide, assigns each an evidence tier based on the quality of published research, and flags the gap between what has been demonstrated in humans and what has only been extrapolated from animal models or online anecdote.

How we rank evidence

Every peptide in this guide is graded on a four-tier evidence scale. Tier 1 means human randomized trials exist or the compound holds current FDA approval. Tier 2 means weaker human data or a discontinued approval. Tier 3 means animal-only data with a plausible mechanism. Tier 4 is preclinical or anecdotal. A lower tier means unproven, not necessarily ineffective.

Throughout this article, each peptide receives one of four evidence tiers reflecting the highest-quality research available for its muscle-related claims. Tier 1 means human randomized controlled trials exist, or the compound currently holds FDA approval for a related indication: the gold standard. Tier 2 means human data exists in a weaker form, such as observational studies, small clinical trials, or a prior FDA approval that has since been discontinued. Tier 3 means the effects have been demonstrated in animal models with a strong mechanistic rationale, but human data is limited or absent. Tier 4 is preclinical or anecdotal: in-vitro data, theoretical mechanisms, or effects that are primarily community-reported.

A lower tier does not necessarily mean a peptide is ineffective. It means the evidence has not yet reached the bar needed for a confident clinical recommendation. For a full breakdown of how peptide research is evaluated, see our clinical evidence module.

Growth hormone secretagogues

Growth hormone secretagogues raise GH and IGF-1 through the pituitary or ghrelin receptor. Tesamorelin is FDA-approved for visceral fat loss, with modest lean-mass evidence pooled across the drug class. MK-677 raised fat-free mass but not strength, and a separate MK-677 trial was stopped early for a heart-failure signal. The CJC-1295 plus ipamorelin stack has never been tested together in humans.

The largest and most studied class of muscle-relevant peptides works by stimulating the pituitary gland to release more growth hormone (GH). Elevated GH drives IGF-1 production in the liver, which in turn promotes protein synthesis. There are two main subtypes: GHRH analogs, which mimic the natural GH-releasing signal, and ghrelin mimetics, which activate the GH secretagogue receptor.

Tesamorelin (Egrifta): tier 1

Tesamorelin is the strongest evidence story in this class. It is a 44-amino-acid GHRH analog that is FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. The pivotal 26-week trial in 412 patients found visceral adipose tissue fell 15.2% on tesamorelin versus a 5.0% increase on placebo, alongside an 81.0% rise in IGF-1 and improved triglycerides; lean body mass rose modestly as well, about 1.3 kg by DXA, but the trial was built around visceral fat and did not test strength or physical performance [1]. A separate systematic review of ten placebo-controlled trials across the GH-axis drug class, tesamorelin, GHRH, GH, and IGF-1 pooled together, found a modest overall increase in lean body mass of about 1.3 kg alongside the fat reduction, though the effect varied by drug subclass and was not isolated to tesamorelin alone [2]. Tesamorelin's approval is specific to HIV-associated lipodystrophy, not muscle building, but the mechanism it relies on, amplified pulsatile GH release, is the same one bodybuilders are interested in for body composition.

Sermorelin (Geref): tier 2

Sermorelin is the first 29 amino acids of natural GHRH. It was previously FDA-approved for diagnosing and treating GH deficiency, and its manufacturer discontinued it in 2008. The FDA later determined only that it was not withdrawn for reasons of safety or effectiveness, and never stated what the reason was. It has a shorter half-life than CJC-1295, requiring more frequent dosing, and produces a more physiological GH release pattern [3]. No controlled trial has reported muscle or strength outcomes for it. It remains available through compounding pharmacies.

CJC-1295 and ipamorelin: tier 3

CJC-1295 is a 30-amino-acid GHRH analog with a drug affinity complex that extends its half-life to five to eight days. A trial in healthy adults found a single dose produced sustained, dose-dependent elevations in GH (2 to 10-fold) and IGF-1 (1.5 to 3-fold) lasting more than a week [4]. Ipamorelin is a 5-amino-acid ghrelin mimetic that was the first growth hormone secretagogue shown to release GH selectively, without the cortisol or prolactin elevation seen with earlier secretagogues [5]. The two are frequently stacked in compounding-pharmacy protocols on the theory that CJC-1295 extends the GH release window while ipamorelin triggers the pulse.

That combination itself, however, has not been tested together in any published human trial. Despite a specific lean-mass figure that circulates in online discussions of this stack, an extensive search turned up no meta-analysis or randomized trial of CJC-1295 plus ipamorelin together. What is documented is that each drug individually raises GH and IGF-1; whether that translates into measurable muscle growth, and how it would compare with resistance training alone, has never been directly studied in humans for this combination.

MK-677 (ibutamoren): tier 2, with caveats

MK-677 is not technically a peptide: it is a small-molecule oral GH secretagogue that activates the ghrelin receptor. It is included here because it is constantly grouped with muscle-building peptides in online discussions. In a 2-year randomized, placebo-controlled trial in 65 healthy older adults, MK-677 at 25 mg per day increased fat-free mass by about 1.1 kg over 12 months, compared with a 0.5 kg loss on placebo, but the fat-free mass gain did not translate into improved strength or physical function [6]. Part of that gain tracked with intracellular water, meaning some of it may not represent new contractile tissue, and fasting glucose rose while insulin sensitivity declined in the treated group.

A separate randomized trial of MK-677 in hip-fracture patients raised IGF-1 substantially but was terminated early after a safety signal for congestive heart failure emerged in a subset of patients; the authors concluded the drug had an unfavorable safety profile in that population [7]. MK-677 is not FDA-approved for any indication. Across both trials, the same pattern repeats: GH and IGF-1 rise reliably, while strength and function do not follow.

Recovery peptides: BPC-157 and TB-500

Recovery peptides do not build muscle directly; they aim to speed tissue repair after injury. BPC-157 has strong rat data for ligament and muscle-tendon healing and one small human study on knee pain relief, but no controlled human trials. TB-500 speeds early cell migration in mice, but a chronic-dosing dystrophy study found no strength or fibrosis improvement. Neither is FDA-approved.

Recovery peptides do not build muscle directly. Instead, they aim to accelerate tissue repair after injury, potentially allowing a faster return to training. The faster an athlete recovers, the more training volume can accumulate, and training volume is what actually drives hypertrophy.

BPC-157: tier 3

BPC-157 (body protection compound-157) is a 15-amino-acid gastric pentadecapeptide with an extensive animal literature on tissue repair. In a rat study, it improved healing of a surgically transected medial collateral ligament, producing consistent functional, biomechanical, and histological improvements over 90 days [8]. A broader review of the compound's effects on striated, smooth, and heart muscle describes BPC-157 supporting recovery at the myotendinous junction, the site where muscle and tendon meet, across rat injury models [9].

Human evidence is far thinner. A retrospective chart review of 16 patients who received intra-articular BPC-157 injections for knee pain, some combined with thymosin beta-4, found 14 of 16 (87.5%) reported meaningful pain relief, with no imaging or functional testing used to confirm the mechanism [10]. There are no large-scale randomized controlled trials in humans. BPC-157 is classified as research-only and is not FDA-approved.

TB-500: tier 3

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and wound repair. In an acute mouse skeletal-muscle injury model, injury itself triggered a local rise in thymosin beta-4, which acted as a chemoattractant that sped the migration of myoblasts (muscle precursor cells) toward the injury site and accelerated wound closure in culture [11]. That is a real, specific finding, but it describes early cellular signaling, not a measured functional outcome.

The more sobering data point comes from a 6-month study of chronic thymosin beta-4 dosing in the mdx mouse, a model of Duchenne muscular dystrophy. Treated mice showed more actively regenerating muscle fibers, but no significant improvement in skeletal muscle strength or in fibrosis compared with untreated mice [12]. The closest published analogue to a chronic TB-500 protocol, in other words, produced a cellular-level signal without a matching functional or structural benefit. There are zero human clinical trials on TB-500. It is banned by WADA and classified as research-only.

IGF-1 LR3

IGF-1 LR3 is a lab-modified analog of IGF-1 with a longer half-life. The 1992 rat study that established the name found it was about 2.5 times more potent than native IGF-1 at reversing a drug-induced catabolic state, not at building muscle in healthy animals. No human muscle-building data exists for it. Documented risks include hypoglycemia, insulin resistance, and mitogenic potential.

IGF-1 LR3 is a modified analog of insulin-like growth factor 1 with an extended half-life, engineered to bind poorly to IGF-binding proteins in blood so more of it reaches tissue. In the 1992 rat study that introduced it, IGF-1 LR3 and a related truncated variant were approximately 2.5 times more potent than native IGF-1 at reversing a catabolic state induced by the steroid dexamethasone [13]. That is a study of reversing drug-induced muscle wasting in rats, not of building new muscle in a healthy animal or human. IGF-1 is the downstream mediator of growth hormone's muscle-building effects, so bypassing GH entirely and delivering an IGF-1 variant directly sounds appealing in theory.

In practice, the safety concerns are substantial. IGF-1 signaling accelerates cell division indiscriminately: it does not distinguish between muscle cells and other rapidly dividing cells. Documented risks in the broader IGF-1 literature include hypoglycemia, insulin resistance, fluid retention, and mitogenic (tumor-promoting) potential with long-term use. Human evidence for muscle building specifically, as opposed to reversing an experimentally induced catabolic state in rats, does not exist. IGF-1 LR3 is not FDA-approved and is banned in competitive sports.

Follistatin and myostatin inhibitors

Myostatin is a natural brake on muscle growth; follistatin inhibits it. Myostatin-null mice grow individual muscles two to three times normal size, and follistatin-overexpressing mice show comparably dramatic increases. In monkeys, gene-delivered follistatin increased muscle size and strength. Human trials exist only for muscle-wasting disease via gene therapy, not injectable peptides for healthy adults.

Myostatin is a protein that acts as a natural brake on skeletal muscle growth. Mutations that knock it out produce the famously hyper-muscular double-muscled cattle breeds and a handful of documented cases in humans. In the mouse studies that established this pathway, animals with the myostatin gene disrupted grew individual muscles that weighed two to three times more than those of normal mice, from a combination of more muscle fibers and larger ones [15]. Follistatin is a naturally occurring protein that inhibits myostatin, effectively releasing the same brake without altering the myostatin gene itself.

The preclinical follistatin data is similarly dramatic. Transgenic mice engineered to overexpress follistatin showed increases in muscle mass that the researchers who created them described as comparable to the myostatin-knockout benchmark above [14]. In cynomolgus macaque monkeys, a single AAV1-FS344 gene-therapy injection into the quadriceps produced pronounced, durable increases in muscle size and strength with no detected harm to other organs [16].

The clinical picture in humans is different. Trials exist only in the context of muscle-wasting disease, not muscle building in healthy people. A small phase 1/2a trial injected the AAV1.CMV.FS344 vector directly into the quadriceps of six Becker muscular dystrophy patients: four of the six improved their 6-minute walk distance by 29 to 125 meters, one showed no change, and muscle biopsies showed reduced fibrosis and more normal fiber size at the higher dose [17]. That is direct intramuscular viral-vector gene delivery in a six-person trial for a specific muscle-wasting disease, not an injectable peptide product for healthy adults. The follistatin peptide products sold online are unregulated, and their bioavailability, potency, and safety in that form are unverified.

MOTS-c: the exercise mimetic

MOTS-c is a mitochondrial-derived peptide nicknamed exercise in a bottle because it activates AMPK and improved running capacity in mice. A single bout of cycling raised MOTS-c nearly 12-fold in human skeletal muscle. But it works through metabolic pathways, not the mechanical loading that drives hypertrophy, and no trial has tested it for muscle growth or strength in humans.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that has earned the nickname "exercise in a bottle" because it activates AMPK, the same master energy sensor engaged during physical exercise, and increases expression of the muscle glucose transporter GLUT4 [18]. In mouse studies, MOTS-c treatment improved running capacity independent of body weight and supported muscle metabolism and physical performance in young, middle-aged, and old animals alike [19]. In a small human study, a single bout of cycling exercise increased endogenous MOTS-c protein in skeletal-muscle biopsies by nearly 12-fold [19].

The "exercise mimetic" label is misleading for muscle building specifically. MOTS-c operates primarily through metabolic pathways, glucose handling and mitochondrial signaling, rather than the mechanical loading and protein-synthesis pathways that drive hypertrophy. Exercise itself provides cardiovascular conditioning, neuromuscular coordination, and musculoskeletal loading that MOTS-c does not replicate. All of the muscle-related evidence above is preclinical or limited to a single small human biopsy study; no trial has tested MOTS-c for muscle growth or strength in humans. For a deeper comparison of exercise-mimic compounds, see our exercise-mimic peptide explorer.

The evidence tier summary

Across every peptide covered here, evidence quality ranges from a single FDA approval for a non-muscle indication down to mouse-only data. Tesamorelin sits at the top with a real approval; MOTS-c sits at the bottom with preclinical signals only. This table summarizes the tier, the actual key finding, and the FDA status for each compound discussed above.

Here is every peptide discussed in this article organized by evidence quality for muscle-related outcomes, with the key finding stated as conservatively as the underlying study allows:

What actually builds muscle

No peptide has been proven in large human trials to build skeletal muscle better than progressive resistance training and adequate protein intake. The popular CJC-1295 plus ipamorelin stack has no published muscle-outcome data at all. MK-677 added mass but not strength, and recovery peptides have not been shown to directly stimulate hypertrophy in a controlled human trial.

The uncomfortable conclusion from the evidence is that no peptide has been proven in large human trials to build skeletal muscle better than progressive resistance training and adequate protein intake. The CJC-1295 plus ipamorelin combination has no published muscle-outcome data at all, despite figures that circulate online. MK-677 added fat-free mass but not strength. The recovery peptides may accelerate cellular repair signaling, but they have not been shown to directly stimulate hypertrophy in a controlled human trial.

This does not mean peptides have no role. GH secretagogues may improve body composition in GH-deficient or muscle-wasting populations, and recovery peptides may plausibly reduce downtime between training sessions, though that specific outcome also has not been directly tested. But the foundation, progressive overload, adequate dietary protein, sufficient sleep, and a sustained training stimulus, is not replaceable by any peptide discussed here. Marketing that presents a peptide as a shortcut around that foundation is not supported by the evidence in this article.

Safety considerations

Beyond individual peptide risks, unregulated muscle-building peptide products carry systemic concerns: unverifiable purity and potency, chronically elevated GH and IGF-1 linked to certain cancers and insulin resistance, possible suppression of natural GH output, and drug interactions for compounds that affect insulin sensitivity. A recent sports-medicine review found human safety data scarce across this entire unapproved-peptide category.

Beyond the risks specific to each compound, there are systemic concerns with unregulated muscle-building peptide products as a category. These products are sold outside pharmaceutical manufacturing standards, so buyers have no reliable way to verify purity, concentration, or sterility before use; a 2026 sports-medicine review of exactly this class of compounds concluded that while many unapproved peptides show favorable outcomes in animal models, rigorous human safety data remain scarce and the potential for patient harm is real [20]. Chronically elevated GH and IGF-1, the mechanism shared by every secretagogue in this article, are associated in the broader endocrinology literature with increased risk of certain cancers, joint pain, carpal tunnel syndrome, and insulin resistance. Exogenous GH secretagogues may also downregulate the pituitary's own GH output over time through negative feedback, and compounds that affect insulin sensitivity, including MK-677 and IGF-1 LR3, can interact with diabetes medications and other metabolic drugs.

For a comprehensive supplier evaluation framework, use our peptide safety checker.

One angle that gets overlooked in muscle-building discussions is the asymmetry between tendon adaptation and muscle recovery. Tendons respond to loading more slowly than muscle tissue, which means a peptide that speeds muscle recovery can still leave connective tissue as the limiting factor; the guide to tendon vs muscle adaptation explains why that gap matters. Understanding whether a peptide is a modified analog of something the body already makes or a fully synthetic design also shapes how to interpret preclinical data; the natural vs synthetic peptides explainer covers those origin categories and what they imply about mechanism and risk.